Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T sip-T with concurrent vs sequential enzalutamide enz administration in metastatic castration-resistant prostate cancer mCRPCReport as inadecuate




Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T sip-T with concurrent vs sequential enzalutamide enz administration in metastatic castration-resistant prostate cancer mCRPC - Download this document for free, or read online. Document in PDF available to download.

Journal for ImmunoTherapy of Cancer

, 3:P145

First Online: 04 November 2015DOI: 10.1186-2051-1426-3-S2-P145

Cite this article as: Drake, C.G., Quinn, D., Dreicer, R. et al. j. immunotherapy cancer 2015 3Suppl 2: P145. doi:10.1186-2051-1426-3-S2-P145 Download fulltext PDF



Author: Charles G Drake - David Quinn - Robert Dreicer - Emmanuel Antonarakis - Neal Shore - John Corman - Raoul Concepcion - Chri

Source: https://link.springer.com/



DOWNLOAD PDF




Related documents